Yes, pre-clinical, I think when Imugene say "Imugene will announce further detail from these abstracts at the time of the event" what we may see IMO on the 8-12th November is a new ANN titling:
"Imugene's Completed onCARlytics Investigational Studies Show Encouraging Results and Flags Three New Phase 1 Trials"
Another reason why Imugene sought more funding I believe. Yes, the Annual report said we had the available funds for the existing pipeline, but what if we keep marrying our platform off to other CD19 dance partners? 3 new P1's now, how many more investigational studies will come from this? Even if we half the costs with Eureka/Cellularity etc for the P1's, these could really add up.
A portion of the $80m could be going towards the partnership with ABL, but I see this partnership as more of a building block and a regulatory necessity rather than a done deal. I think we have funding for the next phase 2 study but IMU will probably have to come knocking again for phase 3 funding, which will most certainly be taken up by shareholders with grins from ear to ear!!
All in my opinion of course.
Yes, pre-clinical, I think when Imugene say "Imugene will...
-
- There are more pages in this discussion • 7,597 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
-0.002(3.77%) |
Mkt cap ! $373.3M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $669.7K | 13.07M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1074997 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 1209633 | 6 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |